东亚药业: 东亚药业关于部分限制性股票回购注销完成不调整可转债转股价格的公告

Core Viewpoint - The company has completed the repurchase and cancellation of a portion of restricted stock, which does not lead to an adjustment in the conversion price of its convertible bonds. Group 1: Convertible Bonds Information - The company issued 6.9 million convertible bonds with a total value of 69 million yuan, approved by the China Securities Regulatory Commission on July 6, 2023 [1] - The bonds began trading on the Shanghai Stock Exchange on August 2, 2023, under the name "东亚转债" and code "111015" [2] - The initial conversion price was set at 24.95 yuan per share, which is currently adjusted to 20.28 yuan per share [2] Group 2: Stock Repurchase and Cancellation - The company plans to repurchase and cancel 14,000 shares of restricted stock due to the departure of one incentive recipient [2][3] - The cancellation is expected to be completed by August 27, 2025 [3] Group 3: Conversion Price Adjustment - The conversion price of "东亚转债" will not change as the repurchased restricted stock represents a small proportion of the total share capital [5] - The adjustment formula for the conversion price is outlined in the prospectus, which includes various scenarios such as stock dividends and capital increases [4] - The calculated conversion price remains at approximately 20.28 yuan per share after applying the adjustment formula [5]